JP2009184999A - 経口摂取が可能な天然成分由来の抗がん剤 - Google Patents
経口摂取が可能な天然成分由来の抗がん剤 Download PDFInfo
- Publication number
- JP2009184999A JP2009184999A JP2008028963A JP2008028963A JP2009184999A JP 2009184999 A JP2009184999 A JP 2009184999A JP 2008028963 A JP2008028963 A JP 2008028963A JP 2008028963 A JP2008028963 A JP 2008028963A JP 2009184999 A JP2009184999 A JP 2009184999A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- capsiate
- formula
- food
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 21
- 239000004615 ingredient Substances 0.000 title description 3
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 79
- 201000011510 cancer Diseases 0.000 claims abstract description 75
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Natural products COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims abstract description 47
- 235000013305 food Nutrition 0.000 claims abstract description 47
- 150000001875 compounds Chemical class 0.000 claims abstract description 46
- ZICNYIDDNJYKCP-SOFGYWHQSA-N capsiate Chemical compound COC1=CC(COC(=O)CCCC\C=C\C(C)C)=CC=C1O ZICNYIDDNJYKCP-SOFGYWHQSA-N 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 230000002265 prevention Effects 0.000 claims abstract description 19
- RBCYRZPENADQGZ-UHFFFAOYSA-N Dihydrocapsiate Chemical compound COC1=CC(COC(=O)CCCCCCC(C)C)=CC=C1O RBCYRZPENADQGZ-UHFFFAOYSA-N 0.000 claims abstract description 15
- BXBVPYSHEOQGHP-UHFFFAOYSA-N Nordihydrocapsiate Chemical compound COC1=CC(COC(=O)CCCCCC(C)C)=CC=C1O BXBVPYSHEOQGHP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims description 20
- 201000001441 melanoma Diseases 0.000 claims description 10
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 8
- 230000000694 effects Effects 0.000 abstract description 20
- 208000018556 stomach disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 22
- 238000010172 mouse model Methods 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 229960002504 capsaicin Drugs 0.000 description 9
- 235000017663 capsaicin Nutrition 0.000 description 9
- 206010027476 Metastases Diseases 0.000 description 8
- 235000009508 confectionery Nutrition 0.000 description 8
- 230000009401 metastasis Effects 0.000 description 8
- 235000002566 Capsicum Nutrition 0.000 description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 201000005202 lung cancer Diseases 0.000 description 7
- 208000020816 lung neoplasm Diseases 0.000 description 7
- 210000000689 upper leg Anatomy 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 210000001165 lymph node Anatomy 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- ZENOXNGFMSCLLL-UHFFFAOYSA-N vanillyl alcohol Chemical compound COC1=CC(CO)=CC=C1O ZENOXNGFMSCLLL-UHFFFAOYSA-N 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- 240000008574 Capsicum frutescens Species 0.000 description 5
- 229940041181 antineoplastic drug Drugs 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 240000004160 Capsicum annuum Species 0.000 description 4
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 4
- 239000006002 Pepper Substances 0.000 description 4
- 241000722363 Piper Species 0.000 description 4
- 235000016761 Piper aduncum Nutrition 0.000 description 4
- 235000017804 Piper guineense Nutrition 0.000 description 4
- 235000008184 Piper nigrum Nutrition 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- -1 fatty acid ester Chemical class 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 230000037182 bone density Effects 0.000 description 3
- 239000001390 capsicum minimum Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000019633 pungent taste Nutrition 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- GVOIABOMXKDDGU-XRODXAHISA-N (3S,3'S,5R,5'R)-3,3'-dihydroxy-kappa,kappa-carotene-6,6'-dione Chemical compound O=C([C@@]1(C)C(C[C@H](O)C1)(C)C)/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC(=O)[C@]1(C)C[C@@H](O)CC1(C)C GVOIABOMXKDDGU-XRODXAHISA-N 0.000 description 2
- GVOIABOMXKDDGU-LOFNIBRQSA-N (3S,3'S,5R,5'R)-3,3'-dihydroxy-kappa,kappa-carotene-6,6'-dione Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C(=O)C1(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CC(O)CC2(C)C GVOIABOMXKDDGU-LOFNIBRQSA-N 0.000 description 2
- OCALSPDXYQHUHA-FNORWQNLSA-N 8-Methyl-6-nonenoic acid Chemical compound CC(C)\C=C\CCCCC(O)=O OCALSPDXYQHUHA-FNORWQNLSA-N 0.000 description 2
- 235000007862 Capsicum baccatum Nutrition 0.000 description 2
- 235000002568 Capsicum frutescens Nutrition 0.000 description 2
- GVOIABOMXKDDGU-SUKXYCKUSA-N Capsorubin Natural products O=C(/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C(=O)[C@@]1(C)C(C)(C)C[C@H](O)C1)\C)/C)\C)/C)[C@@]1(C)C(C)(C)C[C@H](O)C1 GVOIABOMXKDDGU-SUKXYCKUSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 239000012830 cancer therapeutic Substances 0.000 description 2
- 239000001728 capsicum frutescens Substances 0.000 description 2
- 235000009132 capsorubin Nutrition 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 2
- 201000000182 femoral cancer Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 235000012658 paprika extract Nutrition 0.000 description 2
- 239000001688 paprika extract Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- PBPKUNGABCJYBB-UHFFFAOYSA-N 2-methylnon-3-ene Chemical group CCCCCC=CC(C)C PBPKUNGABCJYBB-UHFFFAOYSA-N 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 101100460719 Mus musculus Noto gene Proteins 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000011040 TRPV Cation Channels Human genes 0.000 description 1
- 108010062740 TRPV Cation Channels Proteins 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 239000001511 capsicum annuum Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014899 intrahepatic bile duct cancer Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000010453 lymph node cancer Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 235000019685 rice crackers Nutrition 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- WRPWWVNUCXQDQV-UHFFFAOYSA-N vanillylamine Chemical group COC1=CC(CN)=CC=C1O WRPWWVNUCXQDQV-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
[5]式(I)で表される化合物がカプシエイト、ジヒドロカプシエイト、又はノルジヒドロカプシエイトであることを特徴とする上記[4]に記載の食品又は食品素材に関する。
マウス黒色腫B16細胞から選択された転移実験モデルとして確立し、リンパ行性、血行性に転移しやすく、結節状病変が全身のあらゆる部位に発生しうる悪性黒色腫B16細胞を用いて転移実験を行った。対数増殖期にある悪性黒色腫細胞B16細胞(RCB1283, RIKEN CELL BANK)を培養後に、リン酸緩衝生理食塩水(PBS)に懸濁した。6週齢の雄性C57BL/6マウス(日本SLC株式会社より購入)に前記悪性黒色腫細胞B16細胞(2×105個)を尾静脈移入し、がん疾患モデルマウスとした。移入した日より1日1回、マウス体重1kgあたりカプシエイト(味の素株式会社製)5mgを前記がん疾患モデルマウスに経口ゾンデを用いて強制経口投与した。前記悪性黒色腫細胞を尾静脈移入後18日目に肺、肝臓、腎臓、リンパ節及び大腿骨の各組織を摘出した。肺、肝臓、腎臓、及びリンパ節については、それぞれ10%ホルマリン溶液に固定し、組織ごとにがん結節数を顕微鏡下で計数した。カプシエイトの代わりに生理食塩水を投与したものを対照がん疾患モデルマウスとした。
上記カプシエイト投与がん疾患モデルマウス及び上記カプシエイト未投与対照がん疾患モデルマウスから摘出した肺のがん結節及び大腿骨の写真及びがん結節数を図1に示す。上記カプシエイト未投与対照がん疾患モデルマウスでは肺、肝臓、腎臓、リンパ節にがん細胞の著しいがん結節の形成が確認されたが、上記カプシエイト投与がん疾患モデルマウスから摘出した肺のがん結節の形成は抑制された。また、骨に形成されたがんについては、上記カプシエイト未投与対照がん疾患モデルマウスから摘出した大腿骨ではがん結節の形成と骨破壊が観察されたが、上記カプシエイト投与がん疾患モデルマウスではがん結節の形成と骨破壊を抑制した。
Claims (5)
- 式(I)で表される化合物がカプシエイト、ジヒドロカプシエイト、又はノルジヒドロカプシエイトであることを特徴とする請求項1に記載の抗がん剤。
- がんが、悪性黒色腫であることを特徴とする請求項1又は2いずれかに記載の抗がん剤。
- 式(I)で表される化合物がカプシエイト、ジヒドロカプシエイト、又はノルジヒドロカプシエイトであることを特徴とする請求項4に記載の食品又は食品素材。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008028963A JP5288397B2 (ja) | 2008-02-08 | 2008-02-08 | 経口摂取が可能な天然成分由来の抗がん剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008028963A JP5288397B2 (ja) | 2008-02-08 | 2008-02-08 | 経口摂取が可能な天然成分由来の抗がん剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009184999A true JP2009184999A (ja) | 2009-08-20 |
JP5288397B2 JP5288397B2 (ja) | 2013-09-11 |
Family
ID=41068616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008028963A Active JP5288397B2 (ja) | 2008-02-08 | 2008-02-08 | 経口摂取が可能な天然成分由来の抗がん剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5288397B2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3006313A1 (fr) * | 2013-05-29 | 2014-12-05 | Centre Nat Rech Scient | Composes naturels et leurs derives, leur preparation et leur utilisation dans le traitement de maladies neurodegeneratives et cardiovasculaires, du cancer, et pour des applications alimentaires ou cosmetiques. |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001158738A (ja) * | 1999-11-30 | 2001-06-12 | Morinaga & Co Ltd | 新規なカプサイシノイド様物質を含有する鎮痛剤、食品及び飼料 |
JP2002114676A (ja) * | 2000-10-06 | 2002-04-16 | Morinaga & Co Ltd | 新規なカプサイシノイド様物質を含有する持久力向上用組成物 |
JP2003018974A (ja) * | 2002-06-17 | 2003-01-21 | Morinaga & Co Ltd | 食品組成物 |
JP2003321361A (ja) * | 2002-05-07 | 2003-11-11 | Morinaga & Co Ltd | カプサイシノイド様物質を含有する抗掻痒組成物およびカプサイシノイド様物質の抗掻痒剤としての使用 |
JP2007291014A (ja) * | 2006-04-25 | 2007-11-08 | Kenji Okajima | カルシトニン遺伝子関連ペプチド産生及び放出促進作用を有する可食性組成物 |
JP2009120544A (ja) * | 2007-11-15 | 2009-06-04 | Tsujido Kagaku Kk | 治療剤 |
-
2008
- 2008-02-08 JP JP2008028963A patent/JP5288397B2/ja active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001158738A (ja) * | 1999-11-30 | 2001-06-12 | Morinaga & Co Ltd | 新規なカプサイシノイド様物質を含有する鎮痛剤、食品及び飼料 |
JP2002114676A (ja) * | 2000-10-06 | 2002-04-16 | Morinaga & Co Ltd | 新規なカプサイシノイド様物質を含有する持久力向上用組成物 |
JP2003321361A (ja) * | 2002-05-07 | 2003-11-11 | Morinaga & Co Ltd | カプサイシノイド様物質を含有する抗掻痒組成物およびカプサイシノイド様物質の抗掻痒剤としての使用 |
JP2003018974A (ja) * | 2002-06-17 | 2003-01-21 | Morinaga & Co Ltd | 食品組成物 |
JP2007291014A (ja) * | 2006-04-25 | 2007-11-08 | Kenji Okajima | カルシトニン遺伝子関連ペプチド産生及び放出促進作用を有する可食性組成物 |
JP2009120544A (ja) * | 2007-11-15 | 2009-06-04 | Tsujido Kagaku Kk | 治療剤 |
Non-Patent Citations (2)
Title |
---|
JPN6013001155; MACHO,A. et al: 'Non-pungent capsaicinoids from sweet pepper synthesis and evaluation of the chemopreventive and anti' Eur J Nutr Vol.42, No.1, 2003, p.2-9 * |
JPN7013000132; PYUN,B.J. et al: 'Capsiate, a nonpungent capsaicin-like compound, inhibits angiogenesis and vascular permeability via' Cancer Res Vol.68, No.1, 2008, p.227-35 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3006313A1 (fr) * | 2013-05-29 | 2014-12-05 | Centre Nat Rech Scient | Composes naturels et leurs derives, leur preparation et leur utilisation dans le traitement de maladies neurodegeneratives et cardiovasculaires, du cancer, et pour des applications alimentaires ou cosmetiques. |
Also Published As
Publication number | Publication date |
---|---|
JP5288397B2 (ja) | 2013-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Correia-da-Silva et al. | Anticancer and cancer preventive compounds from edible marine organisms | |
JP2019203034A (ja) | 癌治療 | |
JP2012526806A (ja) | リコピンおよびレスベラトロールの栄養補助食品 | |
JP6218870B2 (ja) | ジンセノサイドf2を含む非アルコール性肝疾患又はインスリン抵抗性の予防若しくは治療用組成物 | |
AU2019324286B2 (en) | Pharmaceutical composition for treating cancer comprising metal ion-bound ionic compound | |
JP2013056893A (ja) | 口腔咽頭嚥下障害の治療 | |
JP6293099B2 (ja) | ジンセノサイドf2の肝疾患予防又は治療用途 | |
KR20200025221A (ko) | 칼키톡신을 유효성분으로 함유하는 암의 예방, 개선 또는 치료용 조성물 | |
JP5288397B2 (ja) | 経口摂取が可能な天然成分由来の抗がん剤 | |
US20230201255A1 (en) | Composition comprising cinnamaldehyde and zinc to improve swallowing | |
JP2015218145A (ja) | TNF−α産生抑制剤 | |
JP2008074794A (ja) | 肥満予防又は改善剤 | |
JP2004155700A (ja) | 脳血管障害改善剤 | |
JP6201085B1 (ja) | グルタミン酸を有効成分とする味覚障害及び/又は食欲障害の改善剤 | |
JP6861806B2 (ja) | オレアノール酸アセテートを有効成分として含む、薬剤により誘発される腎臓毒性の予防、改善または治療用の組成物 | |
JP2009126830A (ja) | 治療剤 | |
JP2005314435A (ja) | 循環器疾患治療剤および健康食品 | |
KR102515929B1 (ko) | 마그놀롤을 유효성분으로 포함하는 근위축증, 근감소증 또는 근조직 손상 예방 또는 치료용 조성물 | |
JP7156856B2 (ja) | 抗肥満剤 | |
JP7271016B2 (ja) | 骨損失疾患の予防、改善または治療のためのchp(シクロ-ヒスプロ)および副甲状腺ホルモンを含む組成物の用途 | |
RU2780016C1 (ru) | Фармацевтическая композиция для лечения рака, содержащая ионное соединение, имеющее связь с ионом металла | |
KR102224780B1 (ko) | 정향 추출물을 포함하는 대장암 표적치료제의 항암 활성 증진용 조성물 | |
KR101980809B1 (ko) | 귀리껍질 추출물을 포함하는 췌장암의 예방 또는 치료용 약학적 조성물 | |
JP2014185099A (ja) | 細胞増殖抑制剤およびがんの予防・治療剤 | |
KR20240072608A (ko) | 워터코인 추출물 또는 이의 분획물을 포함하는 암의 예방 또는 치료용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110207 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130318 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130528 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130529 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5288397 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |